Expanded Safety Analysis of Pevonedistat, a First-In-Class NEDD8-activating Enzyme Inhibitor, in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Blood Cancer Journal - United States
doi 10.1038/bcj.2017.1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pevonedistat, a Nedd8-Activating Enzyme Inhibitor, Sensitizes Neoplastic B-Cells to Death Receptor-Mediated Apoptosis

Oncotarget
Oncology
2017English

CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Frontiers in Oncology
Cancer ResearchOncology
2019English

FLAMSA-RIC for Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis

Journal of Clinical Medicine
2019English

Selinexor, a First-In-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients With Myelodysplastic Syndromes Refractory to Hypomethylating Agents

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

Acute Myeloid Leukemia With Expanded Erythropoiesis

Haematologica
Hematology
2011English

Evaluation of Azacitidine in Patients With Transplant‑ineligible Myelodysplastic Syndromes and Acute Myeloid Leukemia With Myelodysplasia‑related Changes in a Japanese Clinical Setting

Oncology Letters
Cancer ResearchOncology
2019English

Phase I Dose Escalation Study of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Leukemia Research
Cancer ResearchOncologyHematology
2013English

The NEDD8-activating Enzyme Inhibitor MLN4924 Induces DNA Damage in Ph+ Leukemia and Sensitizes for ABL Kinase Inhibitors

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy